Results from a 9-year Intensive Safety Surveillance Scheme (IS3 ) in miglustat (Zavesca® )-treated patients-Reference-Cited by-同舟云学术

Results from a 9-year Intensive Safety Surveillance Scheme (IS3 ) in miglustat (Zavesca® )-treated patients

Author:

Brand Monika¹,Muller Audrey¹,Alsop Jonathan²,van Schaik Ivo N.³,Bembi Bruno⁴,Hughes Derralynn⁵

Affiliation:

1. Actelion Pharmaceuticals Ltd; Allschwil Switzerland

2. Numerus Ltd; Wokingham UK

3. Academic Medical Center; Amsterdam the Netherlands

4. Regional Coordinator Centre for Rare Diseases; Azienda Ospedaliera Santa Maria della Misericordia di Udine; Udine Italy

5. Royal Free and University College Medical School; London UK

Funder

Actelion Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

Reference15 articles.

1. Actelion Miglustat prescribing information 2014 http://www.zavesca.com/pdf/ZAVESCA-Full-Prescribing-Information.pdf

2. Actelion Miglustat (Zavesca) summary of product characteristics 2014 http://www.eudrapharm.eu/eudrapharm/productDetailsAction.do

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Morbus Gaucher;Therapie-Handbuch - Gastroenterologie und Hepatologie;2024